^
Association details:
| Biomarker: | EGFR L858R |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Ameile (aumolertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A multicenter, open-label, single-arm clinical study of Aumolertinib mesylate as postoperative adjuvant treatment for patients with EGFRm positive stage IB and pure solid stage IA2-3 invasive Non-Small Cell Lung Cancer
Excerpt:
...Patients with primary non-small cell lung cancer with 2 common EGFR mutations（EGFR 19 Del or 21 L858R）; 6. ...
Trial ID:
Source:
Title:
97P - Aumolertinib as adjuvant therapy in postoperative EGFR-mutated stage I-III non-small cell lung cancer with high-risk pathological factors
Published date:
03/23/2023
Excerpt:
Patients underwent completely resected pathologic stage I–III lung adenocarcinoma...Patients were assigned to aumolertinib group (group A): patients with EGFR mutation-positive (exon 19 deletion or L858R) received aumolertinib...At data cut-off, all patients in aumolertinib group have no symptoms of tumor recurrence and continued aumolertinib, the 1-year DFS was 100%. In group B, 64% patients were alive and disease-free...This is the first report that aumolertinib has efficacy in patients with completely resected stage I-III EGFR mutated NSCLC with high-risk pathological factors.
Source:
Title:
A Case of Long PFS by Aumolertinib in Advanced Lung Cancer with Multiple Metastases lncluding Brain Metastasis
Published date:
08/08/2023
Excerpt:
...the initial clinical diagnosis was left lung adenocarcinoma (stage IV), mediastinal lymph node metastasis, brain metastasis, bone metastasis, bilateral pulmonary metastasis, and EGFR L858R mutation (tissue NGS 14 genes)….the treatment was changed to aumolertinib...The efficacy evaluation was PR, with no obvious adverse reactions and the PFS was more than 36 months, and she is still under a close follow-up.
